Febuxostat-thiopurine combination therapy in patients with moderately severe inflammatory bowel disease (IBD): a pilot study of a novel drug combination that may influence thiopurine bioavailability

Trial Profile

Febuxostat-thiopurine combination therapy in patients with moderately severe inflammatory bowel disease (IBD): a pilot study of a novel drug combination that may influence thiopurine bioavailability

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Febuxostat (Primary) ; Mercaptopurine (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 23 Jun 2016 Last checked against Australian New Zealand Clinical Trials Registry record.
    • 29 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top